When the U.S. FDA announced its June 2025 ban on shipping U.S. clinical trial samples to “adversary nations” like China and Russia, the global biotech industry felt an immediate jolt. For U.S. biotechs, the loss of access to China’s high-throughput sequencing services—relied on by ~30% of U.S. clinical trials—threatened supply chain disruptions. For labs and manufacturers worldwide, it also raised the stakes: any clinical sample transport now demands stricter compli...
